Submit manuscript...
eISSN: 2469-2778

Hematology & Transfusion International Journal

Letter to Editor Volume 4 Issue 2

Acquired hemophilia a in a patient undergoing aortic valve replacement with warfarin anticoagulation therapy

Hiroshi Fujita,1 Matsunaga H,1 Mishima H,1 Katayama Y,1 Ishikawa S1

1Department of Cardiovascular Surgery, Tokyo Metropolitan Bokutoh Hospital, Japan
2Department of Transfusion Medicine, Tokyo Metropolitan Bokutoh Hospital, Japan

Correspondence: Hiroshi Fujita, Department of Transfusion Medicine, 4-23-15 Koutoubashi, Sumida-ku, Tokyo 130-8575, Japan, Tel 81-3-3633-6151, Fax 81-3-3633-6173

Received: October 03, 2016 | Published: March 20, 2017

Citation: Matsunaga H, Mishima H, Katayama Y, et al. Acquired hemophilia a in a patient undergoing aortic valve replacement with warfarin anticoagulation therapy. Hematol Transfus Int J. 2017;4(2):48-50. DOI: 10.15406/htij.2017.04.00078

Download PDF

Keywords

aortic valve replacement, hemophilia A, heparin sodium, prednisolone, warfarin, anti-coagulant

Abbreviations

INR, international normalized ratio; aPTT, activated partial thromboplastin time; F VIII, factor VIII; BU, bethesda units; FFP, fresh frozen plasma; RCC, red cell concentrate

Introduction

Spontaneous development of acquired hemophilia A is a rare phenomenon and its origin is usually idiopathic.1 However, acquired hemophilia A has been known to occur after surgery2 and in underlying diseases such as malignancies and autoimmune diseases.1,3 Theodossiades et al.2 reported 7patients with surgery-associated acquired hemophilia2 occurring 1-18days after surgery. The surgeries were mainly abdominal surgeries such as cholecystectomy, enteric section and abdominal wall hernia repair.2 In contrast, acquired hemophilia A rarely occurs in patients undergoing cardiovascular surgery2 or those using the anti-coagulant agent, warfarin.4–5 One case of a patient undergoing coronary artery bypass grafting was noted among 7cases of surgery-associated acquired hemophilia.2 A 66-year-old man underwent aortic valve replacement for severe aortic valve stenosis. After surgery, he was administered warfarin (2mg/day) for anticoagulation and the international normalized ratio (INR) was controlled between 1.8 and 2.0. Approximately 5months later, he suddenly presented with severe subcutaneous hematoma in the extremities without trauma. Clotting activities worsened (INR, 2.81; activated partial thromboplastin time [aPTT], 103 seconds; normal range, 24-39seconds). Although warfarin was stopped and the INR normalized (INR 1.07), the aPTT remained prolonged (aPTT, 88.9seconds). Other anticoagulants such as heparin sodium and dabigatran were not used. Lupus anticoagulant test (dilute Russel viper venom time) was negative. Therefore, we measured the factor VIII (F VIII) clotting activity and its inhibitor’s activity; based on this, the patient was diagnosed with acquired hemophilia A for bleeding tendency (F VIII activity, 1.2%; F VIII inhibitor, 152 Bethesda units [BU]). From the definite diagnosis, prednisolone (1mg/kg) was started. However, active bleeding from the upper gastrointestinal tract suddenly occurred. Massive blood transfusion was given until use of recombinant factor VII therapy. Prior to recombinant factor VII infusion, we administered red cell concentrate (RCC) (26 units) and fresh frozen plasma (FFP) (12units). Two units of RCC (280ml) or 2units of FFP (120ml) were derived from 400ml of donated whole blood in Japan. After recombinant factor VII infusion, RCC (6units) alone was transfused. Factor VIII inhibitor activity lowered (<0.5BU) and bleeding tendency resolved. Prednisolone was tapered gradually and then completely discontinued. Fortunately, relapse of acquired hemophilia A was not noted even without prednisolone (aPTT, 26.7-36.0s). Re-administration of warfarin induced good control of the patient’s anticoagulation (INR, 1.8-2.0) and no relapse of acquired hemophilia A has been seen.

Three reports have presented5 patients with acquired hemophilia A associated with anticoagulation with warfarin;4–6 the 3case reports are shown in Table 1. The 5patients were elderly women (mean age, 68years), while in the present case, the patient was a 66-year-old man. Two among the 5patients were undergoing long-term warfarin therapy for mechanical valve replacement.4–5 We speculate that acquired hemophilia may be masked by warfarin therapy among patients undergoing valve replacement. Therefore, prolonged aPTT during warfarin therapy should be noted and checked if it leads to a diagnosis of complicated acquired hemophilia. The 5patients described previously demonstrated a potential delayed diagnosis of acquired hemophilia during anticoagulation with warfarin. The patient in the present case was also administered warfarin for aortic valve replacement, 5months prior to the onset of hemophilia. He had no history of other diseases, such as malignancy or autoimmune diseases.1 Fortunately, he achieved complete remission on prednisolone and no relapse has been noted after discontinuation of prednisolone. Furthermore, re-administration of warfarin did not induce relapse, while in previous reports, no data was shown on relapse in 2 patients who took warfarin again.4–6 In the present case, because onset of acquired hemophilia occurred approximately 5months after surgery, is it not thought to be surgery-associated.2

Age/gender

Underlining diseases

Bleeding symptom

Clotting tests

Hemostatic control

Immunosuppressive treatment

outcome

Reference

Reason of warfarin use

aPTT (s) FVIII inhibitor (Bethesda units)

72 /F

Mitral valve replacement (10 years ago)

chronic obstructive lung disease

diabetes mellitus

chronic renal failure

Surgery and radiation for Breast cancer (4 years ago)

Limb hematoma

Hematuria

Pulmonary hemorrhage

133 s
4

Vitamin K

Intravenous
Immunoglobulin

RCC

prednisolone

Remission

4

64/F

SLE (38 years ago)

Aortic valve replacement (3 years ago)

Retroperitoneal hematoma

82 s
1

Vitamin K

RCC, FFP

Desmopresin

Intravenous immunoglobulin

Prothrombin complex concentrate

Prednisolone

cyclophosphamide

Remission

5

60/F

SLE (20 years ago)

Deep vein thrombosis

Back hematoma

72 s
12

Vitamin K

RCC, PCC

cyclosporin

Remission

No relapse after re-used warfarin

5

72/F

Atrial fibrillation

Deep vein thrombosis

Retroperitoneal and inguinal hematoma

95 s
2

Vitamin K

RCC, FFP

Factor VII infusion

Prothrombin complex concentrate

Prednisolone

cyclophosphamide

Remission

6

71/F

Systemic sclerosis

Pulmonary hypertension

Bleeding from leg ulcer

81 s
2.2

Warfarin discontinuation

none

Remission

6

Table 1 Clinical features of warfarin-masked acquired hemophilia A

Conclusion

Acquired hemophilia A can be complicated in a warfarin-masked patient undergoing cardiovascular surgery. Immediate and accurate diagnosis of acquired hemophilia A may reduce the usage of transfusion product for bleeding episodes.

Acknowledgements

None.

Conflict of interest

The author declares no conflict of interest.

References

Creative Commons Attribution License

©2017 Matsunaga, et al. This is an open access article distributed under the terms of the, which permits unrestricted use, distribution, and build upon your work non-commercially.